e-Article
mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab
Document Type
Academic Journal
Author
Rapti, Vassiliki; Moirogiorgou, Evangelia; Koliou, Georgia-Angeliki; Papadopoulou, Kyriaki; Binas, Ioannis; Pentheroudakis, George; Bafaloukos, Dimitrios; Bobos, Mattheos; Chatzopoulos, Kyriakos; Chrisafi, Sofia; Christodoulou, Christos; Nicolaou, Irene; Sotiropoulou, Maria; Magkou, Christina; Koutras, Angelos; Papakostas, Pavlos; Kotsakis, Athanasios; Razis, Evangelia; Psyrri, Amanda; Tryfonopoulos, Dimitrios; Pectasides, Dimitrios; Res, Eleni; Alexopoulos, Athanasios; Kotoula, Vassiliki; Fountzilas, George
Source
Oncology Letters. January, 2022, Vol. 23 Issue 1, p1v, p25 p.
Subject
Language
English
ISSN
1792-1074
Abstract
Prognostic and predictive biomarkers are being studied for the diagnosis and treatment of breast cancer. The present study retrospectively assessed the mRNA expression of HER family receptor ligands and of other potential prognostic biomarkers and their association with time to progression (TTP), survival and clinicopathological characteristics in patients with metastatic breast cancer (MBC) treated with trastuzumab. A total of 145 tumour tissue samples were analysed. mRNA expression analysis of the transcripts of interest was performed and the association of these markers with selected clinicopathological parameters was examined. HER2 status was centrally re-evaluated. Only 67.6% of patients were truly HER2-positive according to the central HER2 re-evaluation. Heparin binding epidermal growth factor (EGF)-like growth factor, transforming growth factor [beta]1 (TGFB1) and thyroid hormone receptor [alpha] (THRA) mRNA expression was higher in HER2-positive patients (P=0.026, P
Introduction Breast cancer is a disease characterised by molecular heterogeneity (1,2). Gene expression profling has identified molecular subtypes of breast cancer with differences in prognosis and therapeutic options. In particular, [...]
Introduction Breast cancer is a disease characterised by molecular heterogeneity (1,2). Gene expression profling has identified molecular subtypes of breast cancer with differences in prognosis and therapeutic options. In particular, [...]